Vestmark Advisory Solutions, Inc. Seagen Inc. Transaction History

Vestmark Advisory Solutions, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$187.64 - $206.25 $139,979 - $153,862	-746 Reduced 39.2%	1,157 $222,000
Q1 2023 May 09, 2023	BUY	$127.59 - $203.08 $15,310 - $24,369	120 Added 6.73%	1,903 $385,000
Q4 2022 Jan 20, 2023	SELL	$117.37 - $139.17 $5,164 - $6,123	-44 Reduced 2.41%	1,783 $0
Q3 2022 Nov 03, 2022	SELL	$135.27 - $180.11 $16,232 - $21,613	-120 Reduced 6.16%	1,827 $250,000
Q2 2022 Aug 04, 2022	SELL	$108.81 - $179.33 $5,658 - $9,325	-52 Reduced 2.6%	1,947 $345,000
Q1 2022 Apr 27, 2022	BUY	$119.61 - $157.85 $478 - $631	4 Added 0.2%	1,999 $288,000
Q4 2021 Jan 31, 2022	SELL	$142.57 - $190.86 $3,706 - $4,962	-26 Reduced 1.29%	1,995 $308,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $5,555 - $6,622	-39 Reduced 1.89%	2,021 $343,000
Q2 2021 Aug 09, 2021	SELL	$135.08 - $161.1 $744,696 - $888,144	-5,513 Reduced 72.8%	2,060 $325,000
Q1 2021 May 10, 2021	BUY	$137.51 - $190.8 $765,380 - $1.06 Million	5,566 Added 277.33%	7,573 $1.05 Million
Q4 2020 Feb 04, 2021	BUY	$164.63 - $211.93 $330,412 - $425,343	2,007 New	2,007 $352,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Vestmark Advisory Solutions, Inc., based on Form 13F filings with the SEC.

Stay updated on Vestmark Advisory Solutions, Inc. with notifications on news.